## Bart J A Rijnders

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8781424/publications.pdf

Version: 2024-02-01

		126907	74163
81	8,423	33	75
papers	citations	h-index	g-index
85	85	85	11132
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 49, 1-45.	5.8	2,904
2	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respiratory Medicine, the, 2018, 6, 782-792.	10.7	638
3	Prevention of Catheter-Related Bacteremia with a Daily Ethanol Lock in Patients with Tunnelled Catheters: A Randomized, Placebo-Controlled Trial. PLoS ONE, 2010, 5, e10840.	2.5	429
4	Clinical Implications of Azole Resistance in <i>Aspergillus fumigatus</i> , the Netherlands, 2007–2009. Emerging Infectious Diseases, 2011, 17, 1846-1854.	4.3	381
5	Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients. Science Immunology, 2022, 7, eabo2202.	11.9	337
6	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature Communications, 2020, $11$ , 3436.	12.8	321
7	Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles. Clinical Infectious Diseases, 2013, 57, 513-520.	<b>5.</b> 8	308
8	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	8.2	278
9	Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 68, 1463-1471.	5.8	189
10	Influenza-associated Aspergillosis in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 524-527.	5.6	176
11	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications, 2021, 12, 3189.	12.8	139
12	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Current Opinion in Infectious Diseases, 2018, 31, 471-480.	3.1	133
13	Validation of a New Aspergillus Real-Time PCR Assay for Direct Detection of Aspergillus and Azole Resistance of Aspergillus fumigatus on Bronchoalveolar Lavage Fluid. Journal of Clinical Microbiology, 2015, 53, 868-874.	3.9	130
14	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
15	Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV,the, 2017, 4, e547-e554.	4.7	104
16	Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study. Clinical Infectious Diseases, 2008, 47, 1507-1512.	5.8	92
17	Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infectious Diseases, The, 2016, 16, 1423-1429.	9.1	89
18	Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis1. Emerging Infectious Diseases, 2021, 27, 2892-2898.	4.3	82

#	Article	IF	CITATIONS
19	Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. Open Forum Infectious Diseases, 2015, 2, ofv115.	0.9	79
20	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S260-S274.	5.8	73
21	HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. Journal of Infectious Diseases, 2018, 218, 688-697.	4.0	69
22	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV,the, 2017, 4, e195-e204.	4.7	64
23	Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy. PLoS ONE, 2016, 11, e0159243.	2.5	63
24	High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands. Clinical Infectious Diseases, 2018, 66, 1352-1359.	5.8	59
25	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Medical Mycology, 2020, 58, 444-452.	0.7	50
26	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	8.2	49
27	HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Lancet HIV,the, 2021, 8, e96-e105.	4.7	48
28	Paradoxal Trends in Azole-Resistant <i>Aspergillus fumigatus</i> in a National Multicenter Surveillance Program, the Netherlands, 2013–2018. Emerging Infectious Diseases, 2020, 26, 1447-1455.	4.3	46
29	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors. Journal of Infectious Diseases, 2018, 218, 698-706.	4.0	40
30	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S244-S259.	5.8	40
31	Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 269-277.	8.1	39
32	Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis. Clinical Infectious Diseases, 2021, 73, 460-467.	5.8	38
33	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	5.9	38
34	Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?. Clinical Infectious Diseases, 2020, 71, 1764-1767.	5.8	37
35	Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial. Clinical Microbiology and Infection, 2022, 28, 1278-1285.	6.0	37
36	Highâ€dose posaconazole for azoleâ€resistant aspergillosis and other difficultâ€toâ€treat mould infections. Mycoses, 2020, 63, 122-130.	4.0	35

#	Article	IF	CITATIONS
37	Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial. Pulmonary Pharmacology and Therapeutics, 2008, 21, 855-859.	2.6	32
38	Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS ONE, 2019, 14, e0210179.	2.5	32
39	Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. Nature Communications, 2022, 13, 915.	12.8	32
40	Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 224.	3.9	30
41	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. JAMA Network Open, 2022, 5, e2147375.	5.9	30
42	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.9	28
43	Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. Journal of Antimicrobial Chemotherapy, 2020, 75, 936-941.	3.0	28
44	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. Journal of Infectious Diseases, 2021, 223, 2020-2028.	4.0	28
45	Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. Journal of Hepatology, 2016, 64, 807-812.	3.7	26
46	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azoleâ€resistance. A nationwide survey and rationale for the <scp>DB</scp> â€ <scp>MSG</scp> 002 study protocol. Mycoses, 2018, 61, 656-664.	4.0	26
47	Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19. Journal of Clinical Immunology, 2022, 42, 232-239.	3.8	26
48	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nature Communications, 2022, 13, 2583.	12.8	25
49	Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, 1632-1636.	3.0	24
50	Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life. International Journal of Antimicrobial Agents, 2015, 46, 82-87.	2.5	23
51	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms, 2021, 9, 1543.	3.6	23
52	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. Journal of Clinical Microbiology, 2019, 57, .	3.9	21
53	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. Clinical Infectious Diseases, 2020, 70, 349-350.	5.8	20
54	Point of care aspergillus testing in intensive care patients. Critical Care, 2020, 24, 642.	5.8	20

#	Article	IF	Citations
55	Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. EClinicalMedicine, 2019, 17, 100210.	7.1	19
56	Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients. Clinical Infectious Diseases, 2022, 74, 1271-1274.	5.8	19
57	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. PLoS Medicine, 2020, 17, e1003101.	8.4	18
58	Frequency of Positive <i>Aspergillus</i> Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the Intensive Care Unit. Journal of Clinical Microbiology, 2021, 59, .	3.9	18
59	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2021, 76, 1234-1241.	3.0	14
60	Aspergillus in Critically Ill COVID-19 Patients: A Scoping Review. Journal of Clinical Medicine, 2021, 10, 2469.	2.4	13
61	Significant Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Care in Hospitals Affecting the First Pillar of the HIV Care Continuum. Clinical Infectious Diseases, 2022, 74, 521-524.	5.8	12
62	Echinocandin to fluconazole stepâ€down therapy in critically ill patients with invasive, susceptible <i>Candida albicans</i> infections. Mycoses, 2016, 59, 179-185.	4.0	10
63	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. Open Forum Infectious Diseases, 2022, 9, .	0.9	9
64	Use of Semiautomatic Treatment Advice to Improve Compliance with Infectious Diseases Society of America Guidelines for Treatment of Intravascular Catheter-Related Infection: A Before-After Study. Clinical Infectious Diseases, 2003, 37, 980-983.	5.8	8
65	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. Medical Mycology, 2020, 58, 874-880.	0.7	8
66	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWPâ€EBMT, EORTCâ€IDG and SEIFEM survey. Mycoses, 2020, 63, 420-429.	4.0	7
67	Is HIV-1 viraemia below 20 copies/mL in antiretroviral-treated patients associated with virologic outcome?. Infectious Diseases, 2019, 51, 259-267.	2.8	6
68	Invasive Pulmonary Aspergillosis Goes Viral Again?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 275-277.	5.6	6
69	Evidence Gathered From Randomized Clinical Trials and Observational Studies on the Equivalence of Emtricitabine and Lamivudine. Clinical Infectious Diseases, 2015, 60, 1732-1733.	5.8	4
70	Acute hepatitis C in HIV-negative men who have sex with men in the Netherlands and Belgium: a call for action. Sexually Transmitted Infections, 2018, 94, 297-297.	1.9	4
71	Influenza and Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 69, 2037-2037.	5.8	4
72	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. Critical Care Medicine, 2021, 49, e1265-e1266.	0.9	3

#	Article	IF	CITATIONS
73	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSAâ€FLU study. Mycoses, 2022, 65, 656-660.	4.0	3
74	Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving. Journal of Virus Eradication, 2019, 5, 179-190.	0.5	1
75	Reply to Darcis and Berkhout. Journal of Infectious Diseases, 2018, 218, 2020-2021.	4.0	O
76	Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?. Clinical Infectious Diseases, 2019, 69, 1506-1508.	5.8	0
77	Persistent candida arthritis successfully treated with micafungin instillation and surgery. A case report. Medical Mycology Case Reports, 2020, 27, 29-31.	1.3	O
78	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
79	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		O
80	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
81	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0